| Literature DB >> 29278019 |
Claire Mitchell1,2, Audrey Bowen1, Sarah Tyson3, Paul Conroy1.
Abstract
OBJECTIVE: To evaluate the feasibility of a multicentre randomized controlled trial of ReaDySpeech, an online speech therapy programme for people with dysarthria.Entities:
Keywords: Dysarthria; randomized controlled trial; rehabilitation interventions; stroke
Mesh:
Year: 2017 PMID: 29278019 PMCID: PMC6088453 DOI: 10.1177/0269215517748453
Source DB: PubMed Journal: Clin Rehabil ISSN: 0269-2155 Impact factor: 3.477
Figure 1.CONSORT flow diagram for participants.
Baseline characteristics of participants by treatment allocation.
| Characteristics | ReaDySpeech ( | Usual care ( |
|---|---|---|
| Mean age, years (min–max) | 70 (37–99) | 67 (55–85) |
| Male/female | 18/8 | 12/2 |
| Recruitment location | ||
| Hospital | 16 | 5 |
| Community | 10 | 9 |
| Days post-stroke mean (min–max) | 24 (8–67) | 27 (8–90) |
| Aphasia present (severity) | 2 (mild aphasia) | 2 (mild aphasia) |
| Stroke severity, mean (standard deviation) | ||
| Baseline Barthel Index, 0 dependent, 100 independent | 56 (42.5) | 83 (29.6) |
| Baseline Modified Rankin Scale, 0 no symptoms, 6 death | 3 (1.4) | 2 (1.5) |
| Stroke lesion location: lacunar, partial anterior circulation, total anterior circulation, posterior circulation | Lacunar = 11 | Lacunar = 7 |
Outcome measures from baseline to follow-up.
| Outcome measure | Baseline, mean (standard deviation) | Outcome, mean (standard deviation) | Whole group, mean difference (SD, 95% CIs) | ||||
|---|---|---|---|---|---|---|---|
| All | UC | RS | All | UC | RS | ||
| Impairment: FDA-II | All: 159 (37.5) | UC: 170 (20.2) | RS: 153 (43.3) | All: 179 (32.7) | UC: 184 (20.4) | RS: 177 (38.6) | 21 (21.2, 27.8 to 14) |
| Activity: Dysarthria TOMs | All: 3 (1.0) | UC: 3.5 (0.8) | RS: 3.2 (1.1) | All: 3.7 (0.9) | UC: 3.9 (0.6) | RS: 3.6 (1.1) | 0.5 (0.7, 0.7 to 0.2) |
| Participation: COAST | All: 59 (16.3) | UC: 63.1 (15.0) | RS: 56 (16.7) | All: 67 (16.1) | UC: 71 (15.3) | RS: 65.3 (16.6) | 8.5 (16.6, 14 to 3) |
| Participant reported health quality of life states: EQ-5D-5L | |||||||
| Visual analogue scale, median (IQR) | UC, | RS, | UC, | RS, | |||
| EQ-5D-5L | Baseline problems (%) | Outcome problems (%) | |||||
| Mobility | UC 9 (64) | RS 24 (92) | UC 8 (57) | RS 16 (70) | |||
| Self-care | UC 7 (50) | RS 21 (81) | UC 3 (21) | RS 15 (65) | |||
| Usual activity | UC 8 (57) | RS 24 (92) | UC 7 (50) | RS 24 (92) | |||
| Pain/discomfort | UC 6 (43) | RS 17 (65) | UC 7 (50) | RS 14 (61) | |||
| Anxiety/depression | UC 3 (21) | RS 16 (62) | UC 4 (29) | RS 15 (65) | |||
UC, usual care; RS, ReaDySpeech; FDA-II, Frenchay Dysarthria Assessment II; Dysarthria TOMs, Dysarthria Therapy Outcome Measure activity score; COAST, Communication Outcomes After Stroke Scale.